GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Crinecerfont

Company
Neurocrine Switzerland GmbH
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Crinecerfont and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07536269

    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

    Not yet reported Neurocrine Switzerland GmbH 20 participants Est. completion 2028-03 11 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT03525886

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

    Not yet reported Neurocrine Biosciences 18 participants Est. completion 2020-04-07 6 sites
    Other conditions: CAH - Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT04045145

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

    Not yet reported Neurocrine Biosciences 8 participants Est. completion 2021-07-02 6 sites Stand-alone
    Other conditions: CAH - Congenital Adrenal Hyperplasia
    View official trial listing →
  • Active, not recruiting NCT NCT04490915

    Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

    Not yet reported Neurocrine Biosciences 182 participants Est. completion 2027-08 70 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Active, not recruiting NCT NCT04806451

    Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

    Not yet reported Neurocrine Biosciences 103 participants Est. completion 2027-08 46 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Active, not recruiting NCT NCT07187375

    Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

    Not yet reported Neurocrine Switzerland GmbH 7 participants Est. completion 2029-10-04 3 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.